IMUX Immunic, Inc.

Immunic, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohnís disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of ROR?t; and IMU-856 targets the restoration of the intestinal barrier function. Immunicís lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohnís disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.

$8.33
As of 12/06/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  USA
IPO date:  04/17/2014
Outstanding shares:  26,249,439
Average volume:  159,451
Market cap:   $223,645,220
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    4525EP101
ISIN:        US4525EP1011
Sedol:      BJ0LV13
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.50
PS ratio:   0.00
Return on equity:   -57.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy